Heron Therapeutics | HRTX - Equity Capital And Reserves


Heron Therapeutics reported $14.88M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
ALKERMES USD 1.82B 85.86M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amarin USD 458.89M 6.03M Sep/2025
ANI Pharmaceuticals USD 540.72M 34.91M Dec/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Eisai JPY 889.64B 35.21B Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Insmed USD 738.98M 206.6M Dec/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 693.11M 34.1M Dec/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Surmodics USD 118.9M 753K Sep/2024
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Veracyte USD 1.26B 36.61M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025